HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy.

Abstract
Intratumoral immune cells and ERCC1 expression are likely to play a role in the response of ovarian carcinoma to chemotherapy, but their impact on therapy outcome is still unclear. Therefore, 41 cases of optimally resected high grade serous ovarian carcinomas were examined retrospectively for stromal and intraepithelial lymphocyte populations and ERCC1 status in relation to response to platinum-based therapy. Based on RECIST criteria, 27 patients were classified as responsive and 14 as therapy resistant, respectively. Using immunohistochemistry for CD3, CD8, CD4, TIA1, MUM1 and FOX P3 on representative tumor sections, we quantitatively evaluated the intratumoral density of lymphocyte subpopulations. In addition, ERCC1 protein and mRNA expression were determined by immunohistochemistry using the Steffensen score and quantitative RT-PCR, respectively. Furthermore, ERCC1 SNP's C8092A and codon 118 were analysed. Response to chemotherapy was significantly associated with higher numbers of stromal CD3+ (mean 21.33 lymphocytes/HPF versus 8.21 lymphocytes/HPF, p = 0.002) and CD8+ lymphocytes (mean 9.22 lymphocytes/HPF versus 4.57 lymphocytes/HPF, p = 0.013). Counts of intraepithelial CD3+ and CD8+ lymphocytes, stromal and intraepithelial FOXP3+ and TIA1+ cells, CD4+ lymphocytes, and MUM1+ plasma cells did not reach statistical significance. Neither ERCC1 protein expression (p = 0.232) nor SNPs codon 118 and C8092A of the ERCC1 gene (p = 0.269 and p = 0.543) showed an association with therapy response. The same was true for ERCC1 mRNA levels (p = 0.896), probably due to intratumoral lymphocyte contamination. In conclusion, the density of CD3+ and CD8+ T-cells in tumor stroma proved to be a significant predictor for response to platinum-based therapy, whereas examination of ERCC1 failed to identify therapy-responsive patients.
AuthorsHans Bösmüller, Sophie Haitchi-Petnehazy, Gerald Webersinke, Renate Marschon, Franz Roithmeier, Wolfgang Stummvoll, Tanja Fehm, Margit Klier-Richter, Irina Bonzheim, Annette Staebler, Falko Fend
JournalVirchows Archiv : an international journal of pathology (Virchows Arch) Vol. 459 Issue 2 Pg. 183-91 (Aug 2011) ISSN: 1432-2307 [Electronic] Germany
PMID21713364 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • DNA-Binding Proteins
  • Platinum Compounds
  • RNA, Messenger
  • ERCC1 protein, human
  • Endonucleases
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Cystadenocarcinoma, Serous (drug therapy, genetics, immunology)
  • DNA-Binding Proteins (genetics)
  • Drug Resistance, Neoplasm (genetics, immunology)
  • Endonucleases (genetics)
  • Female
  • Humans
  • Immunohistochemistry
  • Lymphocytes, Tumor-Infiltrating (immunology)
  • Middle Aged
  • Ovarian Neoplasms (drug therapy, genetics, immunology)
  • Platinum Compounds (therapeutic use)
  • Polymorphism, Single Nucleotide
  • RNA, Messenger (analysis)
  • Retrospective Studies
  • Reverse Transcriptase Polymerase Chain Reaction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: